|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9502
|
|
pubmed:dateCreated |
2005-12-12
|
|
pubmed:abstractText |
A consensus has emerged that angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-II receptor blockers (ARBs) have specific renoprotective effects. Guidelines specify that these are the drugs of choice for the treatment of hypertension in patients with renal disease. We sought to determine to what extent this consensus is supported by the available evidence.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1474-547X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
10
|
|
pubmed:volume |
366
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2026-33
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.
|
|
pubmed:affiliation |
Centre for Clinical Pharmacology, Department of Medicine, BHF laboratories at University College London, London, UK. juan.pablo-casas@lshtm.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't,
Meta-Analysis
|
